Phase II Trial of Induction Chemotherapy With Weekly Gemcitabine, Epirubicin, Docetaxel as Primary Treatment of Locally Advanced or Inflammatory Breast Cancer Patients
Upon determination of eligibility, all patients will be receive:
Gemcitabine + Epirubicin + Docetaxel
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Pathologic Complete Response (pCR)
18 Months
No
Denise A. Yardley, MD
Principal Investigator
Sarah Cannon Research Institute
United States: Institutional Review Board
SCRI BRE 51
NCT00193050
November 2001
March 2009
Name | Location |
---|